Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TETRAVI: HLA-matched VSTs for Viral Infections Post-HSCT
NCT04013802Phase 1Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Mar 2021
- Primary completion
- May 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HLA-matched multivirus-specific cytotoxic T lymphocytes in cytomegalovirus infection (CMV), Epstein-Barr virus infection, adenovirus infection and 2 more, sponsored by Baylor College of Medicine. Primary endpoint: Treatment related adverse events at 28 days. Started Mar 2021; status: recruiting.
02
Drugs
HLA-matched multivirus-specific cytotoxic T lymphocytes
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infectionadenovirus infectionBK virus infectionprogressive multifocal leukoencephalopathy (PML)
Beyond the preview
Go deeper on NCT04013802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04013802.